A5020930934- Immune Response and Inflammation
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Hepatitis B Virus Studies
Janssen (Belgium)
2017-2023
Pyrrolo[3,2-d]pyrimidines were identified as a new series of potent and selective TLR7 agonists. Compounds optimized for their activity selectivity over TLR8. This presents an advantage recently described scaffolds that have residual TLR8 activity, which may be detrimental to the tolerability candidate drug. Oral administration lead compound 54 effectively induced transient interferon stimulated gene (ISG) response in mice cynomolgus monkeys. We aimed high first pass effect, limiting...
Background Chronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies limited; cure remains an elusive goal. JNJ-64794964 (JNJ-4964) oral toll-like receptor-7 (TLR7) agonist being evaluated treatment CHB. Here, we investigated capacity JNJ-4964 to induce transcriptomic and immune cell changes in peripheral blood healthy volunteers. Methods Peripheral was collected first-in-human phase 1 trial at multiple time points assess...